Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists

Am J Hematol. 2021 Oct 1;96(10):E373-E376. doi: 10.1002/ajh.26277. Epub 2021 Jul 6.

Authors

Eun-Ju Lee¹, Madhav Seshadri¹, James B Bussel²

Affiliations

¹ Division of Hematology, New York Presbyterian Hospital - Weill Cornell, New York, New York, USA.
² Division of Pediatric Hematology/Oncology, New York Presbyterian Hospital - Weill Cornell, New York, New York, USA.

PMID: 34152624
DOI: 10.1002/ajh.26277

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged
Benzoates / therapeutic use*
Female
Humans
Hydrazines / therapeutic use*
Male
Middle Aged
Pyrazoles / therapeutic use*
Receptors, Fc / therapeutic use*
Receptors, Thrombopoietin / agonists*
Recombinant Fusion Proteins / therapeutic use*
Thiazoles / therapeutic use*
Thiophenes / therapeutic use*
Thrombocytopenia / drug therapy*
Thrombopoietin / therapeutic use*
Treatment Outcome

Substances

Benzoates
Hydrazines
Pyrazoles
Receptors, Fc
Receptors, Thrombopoietin
Recombinant Fusion Proteins
Thiazoles
Thiophenes
avatrombopag
Thrombopoietin
romiplostim
eltrombopag